目的:本研究旨在探讨RPR水平与多发性骨髓瘤(MM)患者预后的预测价值。方法:我们回顾性分析了161例新诊断的MM患者,收集患者临床资料,根据MM的预后确定RPR的最佳截断值,将MM患者分为高RPR组和低RPR组,比较两组之间临床资料的差异性,分析...目的:本研究旨在探讨RPR水平与多发性骨髓瘤(MM)患者预后的预测价值。方法:我们回顾性分析了161例新诊断的MM患者,收集患者临床资料,根据MM的预后确定RPR的最佳截断值,将MM患者分为高RPR组和低RPR组,比较两组之间临床资料的差异性,分析RPR对MM患者预后的影响。结果:RPR最佳截断值为0.115时预测价值最高,高RPR组和低RPR组总生存期(OS)的中位数均未达到,Kaplan-Meier生存分析显示两者间差异具有统计学意义(P 0.115、肌酐 > 177 umol/L是OS的独立预后因素;RPR > 0.115是PFS的独立预后因素(P Objective: The aim of this study was to investigate the prognosis value of RPR of MM patients. Methods: We retrospectively analysed 161 newly diagnosed MM patients, collected patients’ clinical data. According to the best cut off value of RPR on the prognosis of MM, they were divided into high RPR group and low RPR group. The differences in clinical data between the two groups were compared and the influence of RPR on the prognosis of MM was analyzed. Results: The best RPR cut off value was 0.115 when the predictive value was the highest. The median overall survival (OS) was not reached in both the high and low RPR groups, and Kaplan-Meier survival analysis showed that the difference was statistically significant (P 0.115, and creatinine > 177 umol/L were independent prognostic factors for OS;RPR > 0.115 was an independent prognostic factor for PFS (P < 0.05). Conclusion: RPR is a practical and validated prognostic marker for newly diagnosed MM patients, and high RPR is an independent poor prognostic factor for OS and PFS in MM patients.展开更多
对中性粒细胞与淋巴细胞比值(Neutrophil to Lymphocyte Rate,NLR)联合红细胞分布宽度(Red blood cell distribution width,RDW)对于急诊老年脓毒症患者的诊疗价值进行分析与探讨。方法 2023年2月至2024年7月期间,招募180名老年脓毒症患...对中性粒细胞与淋巴细胞比值(Neutrophil to Lymphocyte Rate,NLR)联合红细胞分布宽度(Red blood cell distribution width,RDW)对于急诊老年脓毒症患者的诊疗价值进行分析与探讨。方法 2023年2月至2024年7月期间,招募180名老年脓毒症患者,依据其在急救过程中的休克状态,将其划分为非休克组(112名)与休克组(68名)。入院后随访观察30d,根据患者预后情况分为生存组(n=130)和死亡组(n=50)。对比不同组别患者NLR(中性粒细胞与淋巴细胞比值)、RDW(红细胞分布宽度)值以及NLR、RDW值与急性生理与慢性健康状况评估(Acute Physiology And Chronic Health Evaluation,APACHE Ⅱ)的相关性。结果 急诊时,NLR、RDW以及APACHEⅡ评分比较,休克组较非休克组明显更高(P<0.05);预后死亡组较生存组明显更高(P<0.05)。NLR、RDW单独预测患者死亡风险时,AUC、95%CI显著低于APACHEⅡ评分(P<0.05),二者联合应用时AUC、95%CI与APACHEⅡ评分相当(P>0.05)。结论 NLR、RDW能够较好的评估急诊老年脓毒症患者病情,能够较为准确的预测患者预后情况,二者联合应用的预后评估准确性与APACHEⅡ评分相近。展开更多
文摘目的:本研究旨在探讨RPR水平与多发性骨髓瘤(MM)患者预后的预测价值。方法:我们回顾性分析了161例新诊断的MM患者,收集患者临床资料,根据MM的预后确定RPR的最佳截断值,将MM患者分为高RPR组和低RPR组,比较两组之间临床资料的差异性,分析RPR对MM患者预后的影响。结果:RPR最佳截断值为0.115时预测价值最高,高RPR组和低RPR组总生存期(OS)的中位数均未达到,Kaplan-Meier生存分析显示两者间差异具有统计学意义(P 0.115、肌酐 > 177 umol/L是OS的独立预后因素;RPR > 0.115是PFS的独立预后因素(P Objective: The aim of this study was to investigate the prognosis value of RPR of MM patients. Methods: We retrospectively analysed 161 newly diagnosed MM patients, collected patients’ clinical data. According to the best cut off value of RPR on the prognosis of MM, they were divided into high RPR group and low RPR group. The differences in clinical data between the two groups were compared and the influence of RPR on the prognosis of MM was analyzed. Results: The best RPR cut off value was 0.115 when the predictive value was the highest. The median overall survival (OS) was not reached in both the high and low RPR groups, and Kaplan-Meier survival analysis showed that the difference was statistically significant (P 0.115, and creatinine > 177 umol/L were independent prognostic factors for OS;RPR > 0.115 was an independent prognostic factor for PFS (P < 0.05). Conclusion: RPR is a practical and validated prognostic marker for newly diagnosed MM patients, and high RPR is an independent poor prognostic factor for OS and PFS in MM patients.
文摘对中性粒细胞与淋巴细胞比值(Neutrophil to Lymphocyte Rate,NLR)联合红细胞分布宽度(Red blood cell distribution width,RDW)对于急诊老年脓毒症患者的诊疗价值进行分析与探讨。方法 2023年2月至2024年7月期间,招募180名老年脓毒症患者,依据其在急救过程中的休克状态,将其划分为非休克组(112名)与休克组(68名)。入院后随访观察30d,根据患者预后情况分为生存组(n=130)和死亡组(n=50)。对比不同组别患者NLR(中性粒细胞与淋巴细胞比值)、RDW(红细胞分布宽度)值以及NLR、RDW值与急性生理与慢性健康状况评估(Acute Physiology And Chronic Health Evaluation,APACHE Ⅱ)的相关性。结果 急诊时,NLR、RDW以及APACHEⅡ评分比较,休克组较非休克组明显更高(P<0.05);预后死亡组较生存组明显更高(P<0.05)。NLR、RDW单独预测患者死亡风险时,AUC、95%CI显著低于APACHEⅡ评分(P<0.05),二者联合应用时AUC、95%CI与APACHEⅡ评分相当(P>0.05)。结论 NLR、RDW能够较好的评估急诊老年脓毒症患者病情,能够较为准确的预测患者预后情况,二者联合应用的预后评估准确性与APACHEⅡ评分相近。
